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1. Introduction
1.1. Maternal age
In recent years the prevalence of Down syndrome has been increasing. The increase in the
prevalence might be partly explained by better compilation of statistics on Down syndrome
today. Also, the mean maternal age at first delivery as well as the proportion of older moth‐
ers is increasing in all western countries and the risk of Down syndrome increases with ad‐
vancing maternal age [1]. The proportion of mothers aged 35 years or older in France,
Finland, Germany, Greece and United Kingdom were 15.8 %, 19.0 %, 17.0 %, 14.2 % and 17.2
% in 2001, respectively, in 2008 the proportions were 18.9 %, 18.2 %, 21.8 %, 20.9 % and 20.1
%, respectively (Eurostat). Screening for Down syndrome was first performed in 1970’s us‐
ing advanced maternal age or previous history of chromosomal abnormality. The preva‐
lence of Down syndrome at term rises from 1/1527 at the maternal age of 20 years to 1/895 at
age 30 and to 1/97 at age 40 [11]. Also the gestational age affects the prevalence of Down
syndrome. The estimated rate of fetal loss in Down syndrome pregnancies is 43 % between
gestational week 10 and term, 23 % between gestational week 15 and term and 12 % of
births are stillbirths or result in a neonatal death [12]. Therefore, the risk of Down syndrome
decreases as the pregnancy progresses. Table 1 presents the prevalence of Down syndrome
pregnancies in different maternal age groups according to the gestational age.
Maternal age of 35 years or more used as a screening method can detect approximately
43-61 % of Down syndrome cases [13, 14]. However, the false positive rate (FPR) is high
since the proportion of women aged 35 years or older is approximately 20 % in western
countries. Chorionic villus sampling (CVS) and amniocentesis (AC) carry a 0.5-1.0 % risk of
fetal loss [15]. Maternal age of 35 is an arbitrary threshold and there are better screening
methods available today. The invasive test should not be offered only because of increased
maternal age.
© 2013 Marttala; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Maternal age
(years) Gestational age (weeks)
10 12 14 16 20 40
20 1/983 1/1068 1/1140 1/1200 1/1295 1/1527
25 1/870 1/946 1/1009 1/1062 1/1147 1/1352
30 1/576 1/626 1/668 1/703 1/759 1/895
35 1/229 1/249 1/266 1/280 1/302 1/356
40 1/62 1/68 1/72 1/76 1/82 1/97
45 1/15 1/16 1/17 1/18 1/19 1/23
Table 1. The prevalence of Down syndrome according to maternal age and gestational age. (Modified from Snijders
et al. 1999).
1.2. Second trimester screening
Abnormal levels of specific maternal serum markers were associated with Down syndrome
in 1980’s. Second trimester screening with maternal age and maternal serum markers was
developed consisting of either double, triple or quadruple serum screening. Optimal win‐
dow for second trimester serum screening is between 15 and 22 weeks of gestation. Double
test includes maternal age, maternal serum free beta human chorionic gonadotropin (fβ-
hCG) and alfafetoprotein (AFP). The additional serum markers are unconjugated oestriol
(uE3) in triple screening and uE3 and inhibin-A in quadruple screening. The estimated FPRs
for an 85 % detection rate (DR) for double, triple and quadruple screening are 13.1 %, 9.3-14
% and 6.2-7.3 %, respectively [9, 16]. For a 5 % FPR the DRs for double, triple and quadruple
screening are approximately 59 %, 63 % and 72 %, respectively.
2. Screening for Down syndrome today
Screening for Down syndrome has moved from second trimester to first trimester during
the last two decades. The most popular screening method today is combined first trimester
screening where maternal serum biomarkers fβ-hCG and pregnancy associated plasma pro‐
tein-A (PAPP-A) are used in combination with fetal nuchal translucency (NT) measurement,
ultrasound dated gestational age and maternal age to calculate a woman’s risk for Down
syndrome using a computer based program. The serum markers and NT do not correlate
with each other in chromosomally normal or abnormal fetuses [17]. Each screened woman
has a priori risk which is based on her age and the gestational age. The risk calculation soft‐
ware program uses the Gaussian distributions of NT and serum values of normal and affect‐
ed cases to calculate the LRs. These are described by their means of log10 MoMs, standard
deviations and correlation coefficients between the markers. The screening test performs
well if the Gaussian distributions of the markers in the normal and affected populations are
separated. Alternatively, the screening test is impractical if the distributions overlap widely.
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The median MoMs and standard deviations in the populations influence the degree of the
overlap. A patient-specific risk for each screened woman is calculated by multiplying the a
priori risk based on maternal age with the LR [18-21].
Maternal serum biochemistry reflects the degree of maturity of the placenta rather than direct‐
ly measuring the presence or absence of Down syndrome. These markers have also limita‐
tions,  such  as  the  relatively  narrow gestational  window in  which  they  can  be  used.  In
pregnancies that are affected by fetal chromosomal abnormalities the placental function is im‐
paired and the levels of fβ-hCG and PAPP-A differ from normal pregnancies. The results of
the maternal serum biochemistry are reported as multiples of the median (MoM) specific to
the gestational week. MoM values are calculated by dividing a woman’s marker level by the
median level of that marker for the entire population at that gestational age in each laborato‐
ry. The use of MoM values therefore also allows the interpretation between the results from
different laboratories in different countries. The expected levels of maternal serum markers
are not only affected by maternal age and gestational age but also other factors like maternal
weight, ethnic origin, the presence of insulin dependent diabetes mellitus, multiple pregnan‐
cy, smoking and vaginal bleeding. Screening program takes into account certain variables.
2.1. Screening markers
Human chorionic gonadotropin (hCG) was first purified from the pregnant women’s urine.
hCG is produced by the trophoblastic cells of the placenta from the 10th to 12th day after con‐
ception and it reaches its peak value in maternal circulation at 8 to 10 weeks of gestation. Then,
a rapid decrease is seen and a plateau is reached at 20th week of gestation [22]. hCG was first
used as a second trimester screening marker for Down syndrome. Later, it was shown that the
free beta subunit of hCG (fβ-hCG) is an effective screening marker for Down syndrome in the
first trimester of the pregnancy. In Down syndrome pregnancies maternal serum fβ-hCG lev‐
els are higher than in normal pregnancies during the first trimester of the pregnancy. The re‐
ported DRs for fβ-hCG alone are around 19-42 % for a 5 % FPR [9, 16]. The DR of fβ-hCG for
Down syndrome is better at gestational week 13 than at gestational week 10 [9].
The association between abnormal levels of maternal serum pregnancy associated plasma
protein-A (PAPP-A) and fetal aneuploidy was made in late 1980’s and early 1990’s [22, 23].
PAPP-A levels normally rise during pregnancy all the way to the delivery. PAPP-A is a metal‐
loproteinase that cleaves insulin-growth factor binding protein-4 (IGFBP-4) which binds IGFs
with high affinity thus preventing their interaction with the IGF-receptors that mediate cell
growth and survival signals [24, 25]. IGFs are important in implantation, placental physiolo‐
gy and fetal growth [25]. Therefore, PAPP-A is believed to function as a growth factor of both
fetus and placenta during the pregnancy. PAPP-A levels are lower in Down syndrome preg‐
nancies during the first trimester of the pregnancy but the deviation from normal decreases
with gestational age [20]. The DR for PAPP-A alone is approximately 52 % for a 5 % FPR [16].
Fetal NT in the first trimester of the pregnancy was described as the fluid-filled space under
the skin behind the fetal neck in 1992 [7, 8]. NT is measured during first trimester ultra‐
sound scan at gestational weeks 10-13. Ultrasound scan also offers accurate dating of the
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pregnancy, ascertainment of viable fetus or missed abortion, detection of multiple pregnan‐
cies, accurate dating of the pregnancy, identification of chorionicity and detection of some
major fetal anomalies. NT measurement is not altered in multiple pregnancies or by assisted
reproduction techniques. Large studies in low risk populations have shown the association
between increased NT and chromosomal defects. The combination of maternal age and NT
was reported to have a DR of 63.0-90.0 % for a FPR of 5.0-13.0 % [16, 26]. Therefore, NT
measurement is the best single marker in screening for Down syndrome [16, 27].
The incidence of chromosomal defects is related to the thickness rather than the appearance
of NT [28]. In initial studies, single millimeter cut-offs like 2.5 mm or 3.0 mm were used to
define screen positivity but as it was learned that NT increases with CRL it was realized that
it is important to take gestational age into account [29]. Later certain percentile cut-offs, like
the fetal NT measurement equal to or above the 95th or 99th centile for CRL, were used. To‐
day, most current screening programs advocate the use of gestational age based cut-offs for
risk assessment of MoMs. However, some recent studies like a study of 36120 singleton
pregnancies with complete first trimester NT and serum marker data have concluded that
immediate invasive testing should be offered to all patients with NT measurement of 3 mm
or greater since the addition of the first trimester serum markers do not seem to significantly
reduce the final risk of fetal aneuploidy [30].
Also the risk of other adverse pregnancy outcomes increases with enlarging NT measure‐
ment. Between NT values of the 95th and 99th percentiles, the prevalence of major anomalies
is 2.5 %. With NT measurement of 6.5 mm or larger, the risk is approximately 45 % [31]. The
causes behind increased NT measurement are heterogenic which is in relation to the variety
of adverse pregnancy outcomes that increased fetal NT has been associated with [32]. Con‐
genital heart defect is the most common adverse pregnancy outcome that has been associat‐
ed with increased NT [31]. The prevalence of congenital heart defects in children with Down
syndrome is approximately 43 % [33]. Other suggested mechanisms include impaired or de‐
layed development of lymphatic drainage [34], mediastinal compression and impedence to
venous return caused by for example diaphragmatic hernia or skeletal dysplasias [35, 36],
over-expression of certain collagen genes in trisomic fetuses [37], exomphalos, body stalk
anomaly, fetal akinesia deformation sequence and genetic syndromes [38, 39].
2.2. Performance of the combined first trimester screening
Screening works better among a population where the incidence of the screened condition is
high. Therefore, since the risk of Down syndrome increases with advancing maternal age,
screening works better among the older women. Overall, more than half of the Down syn‐
drome cases occur among the women aged 35 years or older [13, 14]. Reported screening
perfomances are better in studies that have been conducted in high risk populations where
the median maternal age is high and thereby the incidence of Down syndrome is also high.
When the screened population reflects well the general low risk population and united
screening strategy and high quality ultrasound machines are used, reliable screening results
are drawn. Table 2 summarizes the performance of combined first trimester screening for
trisomy 21 in large studies reported in the literature.
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Study Gestation Sample size Trisomy 21
(N)
Incidence of
trisomy 21
Median
age
Women at age of
≥ 35
(%)
Cut-off level DR
%
FPR
%
Bindra et al. 2002 [40] 11 – 14 15030 82 1:175 34.0 47.1 1:300 90.2 5.0
Crossley et al. 2002 [41] 10 – 14 17229 45 1:383 29.9 15.4 1:250 82 5
Wald et al. 2003 [16] 10 – 13 39983 85 1:470 - - 1:310 83 5
Wapner et al. 2003 [42] 10 – 14 8514 61 1:135 34.5 50.0 1:270 85.2 9.4
Malone et al. 2005 [9] 11
12
13
38167 117 1:326 30.1 21.6 1:300 87
85
82
5.0
Rozenberg et al. 2006 [43] 11 – 13 14934 51 1:293 30.9 - 1:250 79.6 2.7
Kagan et al. 2008 [44] 11 – 13 56771 395 1:143 35.4 - 1:200 89 4.6
Okun et al. 2008 [45] 11 – 13 14487 62 1:234 34.0 - 1:200 83.9 4.0
Borrell et al. 2009 [46] 11
12
13
7250 66 1:110 32.0 - 1:250 86
84
83
4.9
5.4
6.1
Kagan et al. 2009 [47] 11-13 19736 122 1:162 34.5 - 1:150 91.0 3.1
Leung et al. 2009 [48] 11 – 13 10363 38 1:272 32.0 27.4 1:300 91.2 5.4
Schaelike et al. 2009 [49] 11-13 10668 59 1:181 - 31.0 1:300 88.1 4.9
Wortelboer et al. 2009 [50] 10 – 14 20293 87 1:233 34.3 "/>36 yr
38.7
1:250 75.9 3.3
Salomon et al. 2010 [51] 11-13 21492 80 1:269 30.7 - 1:250 80.0 8.8
Wright et al. 2010 [52] 7-14 223361 886 1:252 31.9 - 1:100 90.0 3.0
Engels et al. 2011 [16] 9-14 26274
<36 17970
≥36
8304
121
<36
52
≥36
69
1:217
<36
1:346
≥36
1:120
34.1 ≥36 yr
31.6
1:200 95.2 <36
94.5
≥36
95.8
6.6
<36
4.1
≥36
13.0
Marttala et al. 2011 [53] 9 – 13 76949 188 1:409 29.3 19.3 1:250 81.9 4.3
Yeo et al. 2012 [54] 10-13 12585 31 1:406 - - 1:300 87.1 5.1
Peuhkurinen et al. 2012
[55]
9-13 63945
<35
50941
≥35
13004
<35
73
≥35
115
<35
1:876
≥35
1:113
<35
27.9
≥35
37.8
16.9 1:250 <35
74.0
≥35
87.0
<35
2.8
≥35
11.9
Table 2. Performance of first trimester combined screening of Down syndrome in different studies.
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Improving the screening means increase in the DR and decrease in the FPR and thus de‐
crease in the number of invasive procedures needed to detect one case of Down syndrome
and number of procedure related miscarriages. However, with current screening strategies,
increase in DR means an increase also in the FPR. A decrease in invasive procedures is an
important goal and therefore special attention should be given to decreasing the FPR.
As screening performance depends on maternal age the screening program takes into ac‐
count maternal age [55]. DR and FPR increase with advancing maternal age. Worst screen‐
ing performance is among the women aged 25-29 years [14, 43]. The overall screening
performance may be an underestimation or overestimation on individual level depending
on the screened woman’s age. More focus on individual risk in counseling is needed.
Among younger women, the possibility of a false negative screening result is higher and
among older women the possibility of false positive screening result is higher. Possibly, low‐
ering the screening cut-off level among women aged 35 or more could improve the balance
between DR and FPR [14]. For example, in USA, improved prenatal screening tests and in‐
creased availability of screening for also the older women has declined the uptake of inva‐
sive testing over the past decade. Also the risk of procedure related miscarriage affects
women’s decision. The possibility for earlier screening during the first trimester has de‐
creased the number of invasive tests more than the second trimester screening. Also a
screening strategy that excludes maternal age, called advanced first trimester screening,
might be an option among older women.
Most common factor for a false negative screening result is NT. Therefore, appropriate train‐
ing and constant audit as well as possibly the certification of the competence should be re‐
quired from the examiners performing ultrasound scans and NT measurements. Even more
competence will be required if additional ultrasound markers like nasal bone will be includ‐
ed into the screening program. The quality of ultrasound machines is also important.
It is possible to provide pretest counseling, biochemical testing of the mother, and NT meas‐
urement at the same visit and post-test counseling on a combined risk estimate within a one-
hour visit to a one-stop clinic [40]. However, screening performance differs according to the
gestational age. The difference between fβ-hCG MoM values increases between unaffected
and affected pregnancies as the pregnancy progresses. On the contrary, the difference in
PAPP-A values decreases and PAPP-A is more effective screening marker than fβ-hCG. The
maximum separation in PAPP-A levels is seen at 9-10 gestational weeks. Therefore, screen‐
ing works better when PAPP-A is measured during 9-10 weeks of gestation rather than dur‐
ing gestational weeks 7-8 or 11-14. First trimester ultrasound scan is more accurate during
the late first trimester. Therefore it would be rational to draw blood samples for the meas‐
urements of PAPP-A and fβ-hCG at gestational weeks 9-10 and have another visit at 12th
gestational week for the ultrasound scan. Another option could be to measure PAPP-A at
gestational weeks 9-10 and NT and fβ-hCG at 12th gestational week. This could improve
DRs from 90 % to 92 % for a FPR of 3 % and from 93 % to 95 % for a FPR of 5 % [20, 47, 48,
50].
Also, fetal gender has been shown to affect the levels of maternal serum PAPP-A and fβ-
hCG in Down syndrome pregnancies. The levels of fβ-hCG and PAPP-A were shown to be
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significantly increased and NT measurements significantly reduced in women carrying fe‐
male fetuses compared to women carrying male fetuses [51]. In future, NIPD may replace
contemporary prenatal diagnosis in those women who are at risk of fetal chromosomal ab‐
normality after Down syndrome screening. However, at the moment, research should also
focus on improving the sensitivity and specificity of the combined screening. This might
happen by adding new biochemical and sonographic markers into screening.
2.3. Invasive testing
After a positive screening result, a diagnostic test is offered. Also women who are in in‐
creased risk for Down syndrome due to increased maternal age or have a family history of
Down syndrome are offered invasive testing. CVS can be performed at 11-14 weeks of gesta‐
tion and AC from 15 weeks of gestation. CVS and AC carry an approximately 0.5-1 % risk of
miscarriage [15].
2.4. Other investigated screening markers
2.4.1. Additional ultrasound markers
Ductus venosus (DV) shunts approximately half of the well-oxygenated blood from the um‐
bilical vein directly into the inferior vena cava thus bypassing the liver. The blood flow in
the DV is normally forward and triphasic. The waveform of the blood flow has a peak dur‐
ing ventricular systole (S-wave) and diastole (D-wave), during the atrial contraction in late
diastole there is a nadir (A-wave). Abnormal flow in the DV in the first trimester of the preg‐
nancy has been associated with chromosomal abnormalities. The abnormal DV flow has
been reported to detect approximately 65-75 % of the Down syndrome cases for a FPR of
5.0-21 % [56, 57]. Addition of DV assessment to combined screening can improve the DR
from 89 % to 96 % with an increase in FPR from 2.3 % to 2.5 % [58].
Fetal tachycardia has been associated with Down syndrome. However, the results have been
controversial and even when the association has been made the authors have not always sug‐
gested the use of fetal heart rate (FHR) in the screening program. Addition of FHR to com‐
bined screening improves the DR only marginally, from 89 % to 90 % for a FPR of 3.0 % [58].
Frontomaxillary facial (FMF) angle decreases normally with CRL from 85˚ at 45 mm to 75˚ at
84 mm [59]. The FMF angle measurements are above the 95th centile in approximately 69 %
of Down syndrome fetuses and 5 % of euploid fetuses. Addition of FMF angle to combined
screening can improve the DR from 90 % to 95 % for a FPR of 5.0 % [60].
Nasal bone (NB) has been found to be absent or hypoplastic in fetuses with Down syn‐
drome. NB is classified as being absent in cases where NB appears as a thin line, or less
echogenic than the overlying skin suggesting that the NB is not yet ossified. The DR for NB
alone is approximately 73 % for a FPR of 0.5 % [83]. Addition of NB to combined screening
can improve the DR from 89 % to 91 % for a FPR of 2.5 % [58].
Tricuspid regurgitation (TR) is defined by the Fetal Medicine Foundation as when the veloc‐
ity of the flow exceeds 60 cm/s and occurs during at least half of the systole. In some studies,
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however, TR has been defined as when the flow exceeds 80 cm/s [62]. The DR for TR alone is
approximately 59.4 % for a FPR of 8.8 % [63]. Addition of TR to combined screening can im‐
prove the DR from 75 % to 87 % for a FPR of 1.0 % [62]. Table 3 presents the reported DRs
and FPRs for additional ultrasound markers alone and in combination with first trimester
combined screening.
Ultrasound marker Ultrasound marker + maternal age Combined screening + ultrasound
marker
Detection rate (%) False positive rate
(%)
Detection rate (%) False positive rate
(%)
Ductus venosus flow 65-75 5-21 96 2.5
Fetal heart rate - - 90 3
Frontomaxillary facial angle 69 5 95 5
Nasal bone 59.8-73 0.5-2.6 91
97
2.5
5
Tricuspid regurgitation 59.4 8.8 87
96
1
2.6
Table 3. Screening performance of the additional ultrasound markers used alone and in combination with combined
first trimester screening markers.
There is no significant association between DV flow, FMF angle, NB or TR and the com‐
bined screening markers PAPP-A, fβ-hCG and NT [59, 64]. New sonographic markers may
also be used in combination. Inclusion of the new sonographic markers in to screening re‐
quires appropriate training of the examiners and the imagining protocols need to be stand‐
ardized.
2.4.2. Genetic sonogram
Genetic sonogram is an ultrasound examination performed during the second trimester of
the pregnancy. During the genetic sonogram fetuses are evaluated for structural malforma‐
tions and also searched for the sonographic markers of Down syndrome. Main markers in‐
clude nuchal fold, short femur and humerus, pyelectasis, echogenic intracardiac focus,
hyperechoic bowel and any major anomaly. Major abnormalities can be recognized approxi‐
mately in 25 % of the Down syndrome pregnancies [65]. If there are one or more sonograph‐
ic markers present, the baseline risk of Down syndrome increases. Similarly, the absence of
markers conveys a reduction in the risk based on for example combined first trimester
screening, previous chromosomal abnormality or advanced maternal age [66].
Besides major markers there are also minor, “soft”, markers that can be evaluated during the
scan. These include nuchal skinfold of 6 mm or more, choroid plexus cyst, enlarged cisterna
magna over 10 mm, ventriculomegaly 10 mm or more, echogenic intracardiac focus, pericar‐
dial effusion, hydrops, two-vessel umbilical cord, polydactyly, clinodactyly, sandal gap, and
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club foot. The genetic sonogram has been reported to have a DR of 66.6 – 83.0 % for a 6.7 –
19.3 % FPR depending on the population. The screening performance is naturally lower in a
low risk population [67, 68]. Combining the genetic sonogram into combined first trimester
screening can improve the DR from 81 % to 90 % for a 5 % FPR [69].
If major defects are detected during the scan, fetal karyotyping is offered to determine the
underlying cause and the risk of recurrence. Even if the condition, like diaphragmatic her‐
nia, is treatable by a surgery, there might be a chromosomal abnormality behind it. Unlike
major defects, minor defects are common and rarely associated with any other handicap
than chromosomal abnormality. Therefore, detection of a minor defect should lead to a thor‐
ough search for other defects. The risk of a fetal anomaly should be individually evaluated
since it increases with the number of minor defects detected. Second trimester ultrasound
scan will likely have an important role also in the future in the detection of fetal Down syn‐
drome and other chromosomal abnormalities.
2.4.3. Other biochemical screening markers
New biochemical screening markers are under investigation. A disintegrin and metallopro‐
tease 12 (ADAM12) is a glycoprotein that is synthesized by placenta. Lowered levels of
ADAM12 in maternal serum have been associated with Down syndrome and other chromo‐
somal abnormalities such as trisomies 18 and 13 during the early first trimester of the preg‐
nancy but its deviation from normality decreases as the pregnancy progresses [69-71].
ADAM12 is not a good screening marker for Down syndrome during gestational weeks
11-13 since its levels are not significantly different from normal. Although in other chromo‐
somal abnormalities the levels differ significantly from normal, there is a significant associa‐
tion between ADAM12 and fβ-hCG and PAPP-A [95, 96]. Modeled DRs for ADAM12 in
combination with first trimester combined screening markers are 97 % and 89 % for FPRs of
5 % and 1 % at gestational week 12 [70]. However, it seems that no additional benefit could
be obtained be the inclusion of ADAM12 into the first trimester combined screening.
Inhibin A has been long used as a part of second trimester quadruple screening. High levels
of inhibin A in Down syndrome pregnancies have also been found during the first trimester
of the pregnancy. Using inhibin A with combined screening markers during the gestational
weeks 9-11 can achieve an approximately 82.6 % DR for a 1.0 % FPR which is close to the
performance of the integrated test [5].
Placental protein 13 (PP13) levels are not altered significantly in Down syndrome pregnan‐
cies but its levels are significantly decreased in trisomy 18 and 13, Turner syndrome and
triploidy pregnancies [72, 73]. Placental growth factor (PlGF) levels in maternal serum have
been reported to be decreased, increased or the same in Down syndrome pregnancies com‐
pared to unaffected pregnancies during the first and second trimester of the pregnancy. Ac‐
cording to the literature, maternal serum PlGF is potentially useful in first trimester
screening for fetal chromosomal abnormalities.
Using second trimester serum markers AFP, inhibin A and uE3 during the first trimester has
also been studied. For the combination of PAPP-A, fβ-hCG, AFP and NT the estimated DR
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is 87.2 %, when AFP is replaced with uE3 the estimated DR is 87.9 % and for all the markers,
88.3 % for a 5 % FPR [20]. Inhibin A with combination of first trimester combined screening
markers has been shown to achieve DRs of 81.4 % and 82.6 % at gestational weeks 7-8 and
9-11, respectively, for FPRs of 0.9 % and 1 % [5]. The studies on inhibin A have been contro‐
versial and some have found that inhibin A does not increase the screening performance in
the first trimester [74].
Besides the biomarkers mentioned above, also other maternal serum proteins have been
shown to be more abundant in control versus Down syndrome pregnancies in both first and
second trimester of the pregnancy [75]. Large scale prospective studies in low risk popula‐
tions evaluating the new maternal serum biomarkers need to be conducted before these
markers could be implemented into the routine first trimester screening.
2.5. Integrated screening and contingent screening
In 1999 first trimester and second trimester screening were combined to create an integrated
screening method which has been shown to achieve DRs around 85 %, 90 % and 94 % for
FPRs of 1 %, 2 % and 5 %, respectively [76]. After first trimester combined screening is per‐
formed, no risk assessment is provided, instead, women return between gestational weeks
15 and 20 for measurements of serum quadruple markers. These screening methods are then
combined with maternal age and an individual risk for Down syndrome is calculated. The
advantage of integrated screening is its high sensitivity and specificity. However, first tri‐
mester screening results are withheld and the screening results are not available until the
second trimester of the pregnancy. In the FaSTER trial, with a 5 % FPR, modeled DRs for
integrated screening method were 96 %, 95 % and 94 % when the PAPP-A was measured
during the gestational weeks 11, 12 or 13, respectively [9]. In the SURUSS study, integrated
screening achieved a 93 % DR for a 5 % FPR. At an 85 % DR the FPR was 1.2 % [16].
Contingent screening policy was developed to reduce the number of NT measurements
needed. This can be beneficial in the areas where there are no qualified personnel or high-
quality ultrasound machines available or where distances are long. Firstly, first trimester se‐
rum sample is analyzed for the levels of PAPP-A and fβ-hCG. Secondly, women are divided
into three groups, women in low, intermediate and high risk for chromosomal abnormalities
according to the serum markers. Women in low risk are offered no further screening. Wom‐
en in high risk are offered immediate invasive testing. NT screening is offered for those in
intermediate risk and new risk calculation using first trimester serum markers and NT
measurement is performed and invasive testing is offered for those in high risk. This meth‐
od has been estimated to achieve DRs of 67.6 % and 88.6 % for FPRs of 2.3 % and 6.4 %, re‐
spectively [77, 78]. Contingent screening might put women in unequal positions as first
trimester combined screening is known to achieve higher screening performances. More‐
over, major structural abnormalities can be detected during the first trimester ultrasound
scan [79, 80]. Also other variations of contingent screening including for example new sono‐
graphic markers have been developed.
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3. Screening for Down syndrome in the future
3.1. Non-Invasive Prenatal Diagnosis (NIPD)
One of the hottest topics in prenatal medicine today is the noninvasive prenatal diagnosis
(NIPD). Since 1997 many approaches have been made in the field of NIPD and today it is
possible to determine fetal sex, fetal Rhesus D status and diagnose genetic disorders or carri‐
er status for paternally inherited mutations [81]. Women in high risk of X-linked disorders
like hemophilia can be offered noninvasive fetal sex determination. Y chromosome derived
sequences can be found in maternal blood as early as eight weeks of gestation [82]. The de‐
tection of Y chromosome material indicates further investigations but if no evidence of de‐
tectable Y chromosome is found, unnecessary invasive testing with the risk of pregnancy
loss, can be avoided. The costs of NIPD of fetal gender and invasive testing are similar [83,
84]. Y chromosome sequences can be detected with approximately 95.4 % sensitivity and
98.6 % specificity. Best test performance reported is for the real-time quantitative polymer‐
ase chain reaction (RTQ-PCR) after 20 weeks of gestation. Tests performed before seventh
gestational week or using urine sample have been reported to be unreliable [85].
Detection of fetal rhesus D status can reduce the use of D immunoglobulin to prevent im‐
mune hemolytic disease of the newborn. The reported sensitivities and specificities for fetal
Rhesus D sequence are greater than 95 % [86]. Reported false negative results are mainly
due to a lack of fetal DNA in maternal blood sample due to too early gestation or insensitive
methods. The presence of pseudogenes, mainly in African women, can lead to false positive
results. However, current genotyping protocols in molecular diagnostic laboratories ac‐
knowledge the possibility of the pseudogene and do not amplify this region of the genome
[87]. The first study evaluating the national clinical application of NIPD of fetal Rhesus D
status conducted in Denmark, reported a sensitivity of 99.9 % and specificity of 96.5 % [88].
Fetal hemoglobin in maternal circulation was detected in 1956 indicating transplacental
transmission of fetal erythrocytes [89]. Fetal cells were found in maternal blood during preg‐
nancy in 1958 [90]. Nucleated red blood cells have a relatively short lifespan in maternal
blood but other cells can reside in maternal blood for decades after delivery and therefore
cause false positive or negative test results in subsequent pregnancies [87, 91]. Other prob‐
lems besides the possibility of the presence of previous pregnancy include the rare number
of fetal cells in maternal plasma, one cell per ml, and low efficiency of enrichment methods.
CffDNA, originating from the apoptotic trophoblasts derived from the embryo, was first de‐
tected in maternal circulation in 1997 [92, 93]. It has been shown that cffDNA is present in
maternal circulation even before placental circulation has been established. It is present also
in anembryonic gestations. Detected cffDNA sequences in maternal blood have been shown
to reflect the placental genotype in cases of confined placental mosaicism [87]. Compared to
intact fetal cells cffDNA has many advantages; it is almost a thousand times more present in
maternal circulation than fetal cells, its mean half-life in maternal blood is approximately
16-30 minutes making it a marker of the current pregnancy [94, 95]. Even though the concen‐
tration of cffDNA in maternal blood is higher than that of the intact fetal cells, it is still low
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and it only comprises 3-6 % of the total cell-free DNA in maternal blood since the majority
of cell-free DNA is of maternal origin. Also, half of the fetal genome is inherited from the
mother and there are individual differences in the concentration of the total cffDNA [94, 96].
The newest strategy for noninvasive prenatal gene profiling is the maternal blood analysis
of fetal mRNA. Discovery of fetal placenta-specific expressed mRNAs in the maternal serum
and plasma was made in 2000 [97]. Fetal mRNA molecules have been shown to be easily de‐
tectable since they are very stable in maternal blood probably due to the association with
particulate matters [99]. Numerous pregnancy-specific, fetal-specific mRNA transcripts that
are independent from fetal gender and fetal genetic polymorphisms have been identified in
maternal circulation [99, 100]. Studied noninvasive prenatal screening mRNA markers in‐
clude for example placenta-specific 4 (PLAC4) which is cleared rapidly after delivery and
has been reported to have a 90 % DR for a 3.5 % FPR for Down syndrome [100].
3.1.1. Current state of art in NIPD
Various methods for NIPD using cffNA in maternal circulation have been introduced. Mas‐
sively parallel sequencing (MPS) of fetal DNA has high sensitivity and specificity for the de‐
tection of trisomy 21. The reported sensitivities range between 79.1 % and 100 % and
specificities between 97.9 % and 100 %, respectively [101-104]. Similar sensitivities and spe‐
cificities for trisomies 21 and 18 have been reported for targeted MPS method and for triso‐
my 21 with differential methylation and real-time multiplex ligation-dependent probe
amplification (RT-MLPA). One study achieved a 100 % sensitivity and specificity for trisomy
21 by a targeted approach that was based on calculation of haplotype ratios from tandem
single nucleotide polymorphisms (SNP) sequences on chromosome 21 combined with a
quantitative DNA measurement technology [105].
The use of MPS as the screening strategy has been reported to achieve sensitivities of
91.9-100 % and 100 % with specificities of 98.9-100 % and 98.4-100 % for trisomy 18 and tris‐
omy 13, respectively [106-108]. MPS combined with improved z-score test methodology,
was reported to achieve 100 % DR with a 0 % FPR for Down syndrome, trisomy 18, trisomy
13, Turner syndrome and Klinefelter syndrome [109]. High troughput DNA sequencing has
many advantages as the entire process can be automated and multiple samples be analyzed
simultaneously so that thousands of sequencing reactions can occur in parallel as the test
DNA is bound to a solid support such as an array.
One method called the RNA-SNP approach measures the ratio of alleles for a SNP in placen‐
ta-derived mRNA molecules in maternal plasma [100]. PLAC4 mRNA has been used for this
method [110]. The RNA-SNP method detects the deviated RNA-SNP allelic ratio on PLAC4
mRNA which is caused by the imbalance in chromosome 21 dosage. The RNA-SNP strategy
is only suitable to women with a fetus heterozygous for the studied SNP in the PLAC4 gene.
Method can be based on a mass spectrometry (MS) method or digital-PCR which enhances
the precision [100, 111]. Digital-PCR method is more costly but it can be used in analysis of
plasma samples with low concentration of PLAC4 mRNA such in early pregnancy samples.
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Another method used is the measurement of the total concentration of PLAC4 mRNA in
maternal plasma is increased in Down syndrome pregnancies because of the extra gene
copy in the placenta [112]. The mRNA quantification method can be used for pregnancies
with homozygous fetuses. However, it is not yet known if there are other factors such as in‐
creased apoptosis in aneuploid placentas that might contribute to the increase of circulating
PLAC4 mRNA in maternal plasma. The diagnostic accuracies of RNA-SNP approach, using
blood samples from women carrying heterozygous fetuses for the PLAC4 mRNA, on the MS
and digital-PCR platforms have identical sensitivities and specificities of 90-100 % and
89.7-96.5 %, respectively [100, 112].
Also gene sequences present in neonatal and maternal whole blood have been studied [81,
87]. In amniotic fluid, abundant amounts of both cffRNA and cffDNA can be found and the
present cell-free nucleic acids (cffNA) are nearly exclusively of fetal origin. Also, the cffNA
appears to originate from fetal tissues that are either in direct contact with the amniotic fluid
or drain into the amniotic fluid and there seems to be no NA derived from the placenta. In‐
tial studies on the molecular pathophysiology in the living fetus suggest that the majority of
dysregulated gene espression in aneuploid fetuses occurs in genes present in other chromo‐
somes than the one involved in the chromosomal abnormality. Another finding is the oxida‐
tive stress in fetuses affected by Down syndrome which may result in the mental retardation
and Alzheimer’s disease [87]. After birth, analysis of cffNA from neonatal saliva can be used
to monitor neonatal health and development. This offers comprehensive, real-time informa‐
tion regarding many organs and tissues which could allow the monitoring of premature ne‐
onates in terms of health, disease and development [113].
The reported data indicates that highly accurate NIPD of chromosomal abnormalities by
maternal blood sample is achievable during the first trimester of the pregnancy. However,
the gestational window of NIPD is still to be researched. Although studies have reported
high sensitivities and specificities, approximately 1 % FPRs have been reported. Therefore,
at the moment, invasive testing is still required after positive test result and the method
might be more incisively regarded as an “advanced screening test” rather than a diagnostic
test and pregnancy termination should not be offered only based on a positive NIPD test.
However, it has been estimated that 98 % of the invasive procedures could be avoided if AC
or CVS were based on the MPS test results [101]. Most studies to date have been small and
conducted in high risk women. Large-scale objective clinical trials are needed to evaluate the
sensitivity and specificity of NIPD in low risk general populations. The future costs of NIPD
can be only estimated and are dependent on the relative costs of NIPD, Down syndrome
screening and number of invasive tests that are performed.
NIPD of fetal Rhesus D genotype has been widely validated in Europe but it is slower been
undertaken in United States of America. It is anticipated that besides fetal sex determination
and Rhesus D detection, over the next few years also the NIPD of fetal aneuploidy will be
possible and NIPD will be refined to include also other trisomies than trisomy 21. However,
it may take longer to develop proper techniques to detect other pathogenic rearrangements.
Ultrasound scan during the early pregnancy will be necessary even if NIPD would become a
routine screening method. Increased levels of cffNA in maternal blood have been associated,
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besides chromosomal abnormalities, with various pathological conditions like pre-eclamp‐
sia, hemolytic anemia, elevated liver enzymes, low platelets syndrome and placental abnor‐
malities like placenta accrete [87, 114].
3.1.2. Ethics in NIPD
NIPD has many benefits as definitive diagnoses can be made earlier in the pregnancy when
termination of an affected pregnancy is safer, parental anxiety is reduced and costs are de‐
creased. As testing becomes safer the uptake will probably increase and thus additional
health and economic benefits can be reached. However, NIPD also raises many ethical is‐
sues. Counseling needs to be informative so that women could make the decision fully
aware of the consequences of possible findings. At the moment, counseling is offered for ev‐
ery woman but only those who have received a positive screening result are offered more
detailed information about Down syndrome as they are offered invasive testing. The nature
of NIPD, however, is closer to invasive diagnosis than screening. Therefore, all women
should be comprehensively counseled before the testing. This probably requires much more
genetic counselors than are currently available.
In recent years, private sector has been funding research around NIPD. This might lead to
expensive testing. Until now, Down syndrome screening has had a minimal effect on birth
incidence of genetic disorders. As testing becomes safer and more accurate than before more
affected pregnancies may be found and possibly terminated. This might affect the public at‐
titudes towards affected individuals and their families. Women might feel more pressured
by the society to test and terminate affected pregnancies. Also commercial and insurance
sectors might perceive economic benefits in decreasing the prevalence of disorders. As the
technology develops, also less severe disorders, late-onset disorders, nonmedical traits and
predispositions can be detected prenatally. Codes of practice should be developed as well as
regulatory recommendations made [158]. In United States of America, several professional
organizations have stated that noninvasive fetal gender determination should only be of‐
fered for medical indications. However, via the internet the test is available directly to the
consumers and the technology might also be used for fetal sex selection.
Women seem to feel positive about the new improvements in the screening field. However,
they find it hard to fully realize the new choices and consequences that will follow with
NIPD [115]. Among the healthcare providers there seems to be a lack of knowledge or con‐
viction about using NIPD. Healthcare providers hold genetic counseling and professional
society approval important and they are more willing to offer cffDNA testing for chromoso‐
mal abnormalities and single-gene disorders than determination of sex and behavioral or
late-onset conditions. Standards of care and professional guidelines are necessary.
4. Other implications for combined Down syndrome screening method
Using the algorithm for Down syndrome, combined screening detects approximately 55.6 %
of trisomy 18 cases, 36.4 % of trisomy 13 cases and 60 % of other aneuploidies for a 4.3 %
Down Syndrome48
FPR. When specific algorithm for trisomy 18 is used, the DR for trisomy 18 is reported to be
74.0 - 88 % with a slight increase of 0.1 % in the FPR. Using the specific algorithm for triso‐
my 13 improves the DR for trisomy 13 to approximately 54.5 - 73 % for an additional 0.1 %
increase in the FPR [116, 117].
Adverse pregnancy outcomes like pregnancy loss, hypertension, preeclampsia, eclampsia,
preterm delivery, small for gestational age newborns and fetal death cannot yet be predicted
in the early pregnancy. Closer surveillance and possible new treatments could be studied on
women in high risk to avoid the adverse pregnancy outcomes in the future. As well as in‐
creased NT measurements, also abnormal levels of maternal serum biochemical markers
have been associated with pregnancy complications.
5. Ethical aspects of the first trimester screening
Participating in the screening for chromosomal abnormalities and the diagnostic testing is
voluntary. Women have an opportunity to retrieve screening at any point. It is essential that
women make an informed decision when they decide to participate in the screening. When
a positive screening result is received, detailed and objective counseling should be offered
about the condition at issue and about the procedure and its risks. Health professionals’ per‐
sonal opinions should not affect the woman’s decision. However, it is known that the many
issues like the age, level of medical knowledge, opinion about the screening test, specialty
and attitudes towards the patients affect the counseling. Due to the complexity of the screen‐
ing, women need to assimilate a lot of information which might not always be successful. If
the possibility of a chromosomal abnormality is introduced for the first time when the
screening is offered, worry can be caused. The possibility to terminate the pregnancy after a
chromosomal abnormality is detected raises many ethical issues about the right of the disa‐
bled to be born regardless of their disability. Screening is also thought to be insulting to‐
wards people with a chromosomal or a structural anomaly. Screening does not produce
diagnoses, only risks for chromosomal abnormalities. The limitations of the screening
should be told for the women participating in the screening. One redeeming feature of the
screening is that it provides a great deal of knowledge about chromosomal and structural
abnormalities equally for every screened woman.
6. Screening in multiple pregnancies and in ART pregnancies
Screening in multiple pregnancies is more difficult than in singleton pregnancies. Firstly,
maternal serum biochemistry is less effective in multiple pregnancies since placental analy‐
tes from normal fetus/fetuses can mask abnormal levels in the affected fetus. Moreover, ab‐
normal levels of maternal serum biochemical markers cannot distinguish which fetus is the
affected one [118]. Secondly, second trimester ultrasound examination is more challenging
because of the limitations due to the positions of the fetuses and interposition of fetal parts.
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Nuchal translucency measurement together with maternal age, however, has been shown to
be an effective screening method in multiple pregnancies. The DR is comparable to that in
singleton pregnancies for a slightly higher FPR. Also, determination of fetus-specific risk is
possible with this technique. The limitation of ultrasound in twins is that they can be influ‐
enced by hemodynamic imbalance between the twins’ circulation. Other possible screening
markers in multiple pregnancies are DV flow and NB [119-121].
Screening in pregnancies conceived using assisted reproductive technologies (ART) has
been studied by different research groups and contradictory results have been reported. In
some studies fβ-hCG and NT have been enlarged in ART pregnancies and PAPP-A levels
decreased, while others have reported no significant differences in these markers. It seems
that decreased PAPP-A levels in ART pregnancies is the most discriminating factor leading
to increased FPR in these pregnancies. However, some have reported no significant differ‐
ence in FPR in ART pregnancies compared with spontaneous pregnancies [191].
7. Cost-effectiveness of the screening and international differences in
screening strategies
The demands for the prenatal screening performance are high. Also, the cost-effectiveness of
the screening should be good. There are some estimations about the screening costs in differ‐
ent countries but overall, the cost and patient acceptability of the alternative policies of screen‐
ing  tests  depend on  the  existing  infrastructure  of  antenatal  care,  which  varies  between
different countries and centers. Screening and diagnostic tests for chromosomal abnormali‐
ties have been developed and been available for several decades and the research for new
strategies is ongoing. National committees review available evidence and national screening
statistics and each country adopts testing modalities in its own way. In dissimilar healthcare
systems guidelines for best practice evolve different ways. There are differences in what tests
are offered, insurance coverage, counseling and the national legal situation for terminating an
affected pregnancy. Global knowledge about testing practices gets more and more important
for the counselors as people immigrate between the countries and into different cultures. In
Europe, almost 90 % of couples who receive a prenatal diagnosis of Down syndrome decide to
terminate the pregnancy. However, the legal situation concerning pregnancy termination dif‐
fers between countries [123]. Most couples that feel that they would continue the pregnancy
even though the fetus would be diagnosed with a chromosomal abnormality do not partici‐
pate in the screening program [124]. There are significant differences in screening modalities
between for example United Kingdom and the United States of America despite many simi‐
larities between the countries [125]. The introduction of prenatal screening has, however, led
to a reduction in live-births of Down syndrome cases internationally.
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